ArticleInternational urogynecology journal2026
Postoperative Infection Risk in Sacrocolpopexy: Single vs Dual Antibiotic Prophylaxis.
Article in International urogynecology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introduction and hypothesisThe optimal antibiotic prophylaxis for mesh-based prolapse surgery remains uncertain. Although cefazolin is widely used, its limited anaerobic coverage may increase the risk of postoperative infections, particularly in women undergoing concomitant hysterectomy. Evidence from hysterectomy cohorts suggests that adding metronidazole reduces surgical-site infections, prompting evaluation of this approach in laparoscopic mesh-augmented apical prolapse repair. The objective was to compare postoperative infection rates in women receiving single-agent versus dual-agent prophylactic antibiotics.
methodsThis retrospective cohort study included women with pelvic organ prolapse who underwent laparoscopic mesh-augmented apical prolapse repair between 2021 and 2025. Patients received either cefazolin alone or cefazolin plus metronidazole according to the routine practice of the operating urogynecologist. Demographic, operative, and postoperative data were extracted from electronic medical records. The primary outcome was composite postoperative infection within 30 days, including postoperative fever, surgical site or trocar site infection, mesh infection, pelvic abscess, or urinary tract infection. Associations between prophylactic regimen and postoperative infection were evaluated using univariable analyses. The antibiotic prophylaxis regimen was surgeon dependent, with one surgeon routinely administering cefazolin alone and the other cefazolin plus metronidazole. Multivariable logistic regression was performed to adjust for baseline differences between the groups.
resultsA total of 523 women met the inclusion criteria; 204 (39.0%) received dual prophylaxis and 319 (61.0%) received cefazolin alone. Overall composite postoperative infection outcome occurred in 18 out of 523 patients (3.4%). Infection rates of the single-agent and dual-prophylaxis groups were similar (3.7% vs 2.9%, p = 0.64). Rates of postoperative fever, surgical-site infection, and urinary tract infection did not differ significantly between groups. No mesh-related infections or pelvic abscesses were observed. After adjustment for baseline differences, the antibiotic regimen was not significantly associated with the composite postoperative infection outcome (aOR 1.30, 95% CI 0.36-4.64; p = 0.689).
conclusionComposite postoperative infection outcome rates after laparoscopic sacrocolpopexy were low, with no significant difference observed between cefazolin alone and combined cefazolin-metronidazole prophylaxis.
Indexed as
Identifiers
42878791What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.